Experience in developing a tool using the CSSA as a model Kyle M. Kampman M.D. Professor Department of Psychiatry Perelman School of Medicine University.

Slides:



Advertisements
Similar presentations
A comparison of 3 withdrawal scales Jean-François ETTER, PhD Institute of social and preventive medicine University of Geneva, Switzerland John R. HUGHES,
Advertisements

Pain Catastrophizing and Childbirth Satisfaction in a Group of Nulliparous Women Aaron Reposar, Beth D. Darnall, PhD, Katherine Volpe, Hong Li, MD, MPH.
Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.
Depression—There are at least two sides to every story.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
ABCs of Behavioral Support Jonathan Foulds PhD. Penn State – College of Medicine
Amphetamine Addiction in Iceland and efficacy of pharmacotherapy Valgerður Rúnarsdóttir, M.D., Vogur Hospital Iceland SAA National Center of Addiction.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2014.
Evaluating Cocaine Use Outcome Measures: Relationships with Long Term Cocaine Use and Functioning Brian D. Kiluk, Ph.D. Kathleen M. Carroll, Ph.D. Yale.
Medication Development for Methamphetamine Dependence
Prevalence of Alcohol Use Disorders
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,
® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.
Click to edit Master subtitle style The Role of Attachment in brief group therapy for depression: An empirical study Dr Jo Wilson Professor Phil Richardson.
©AMSP Suicidal Behavior, Alcohol, and Alcohol Use Disorders Timothy W. Lineberry, M.D. Assistant Professor, Psychiatry Mayo Clinic.
Research Strategies to Test Behavioral/Psychotherapy Treatments for Substance Use Disorders: Several Examples Richard A. Rawson, Ph.D UCLA ISAP Cairo,
UCLA Integrated Substance Abuse Programs (ISAP). CSAT MTP Project Goals: To study the clinical effectiveness of the Matrix Model To study the clinical.
Factors that Influence Retention in Greek Therapeutic Communities Erianna Daliani MSc (Gerasimos Papanastasatos) KETHEA Research Dept. 11th European Conference.
Audrey J. Brooks, PhD University of Arizona CA-AZ node.
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
Results of the Vivitrol Pilot in Los Angeles County Presented by: Desiree A. Crevecoeur-MacPhail, Ph.D. Research Psychologist, UCLA ISAP.
Does reduction in cocaine use represent psychosocial benefit? Ivan D. Montoya, M.D., M.P.H. Deputy Director, NIDA-DPMC.
Lack of Association of Cannabis Use with Opioid Outcomes among Opioid-Dependent Youth Kevin P. Hill, M.D., M.H.S. a,b, Heather E. Bennett, B.A. a, Margaret.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
Dr. Avinash De Sousa.  State government aided hospital.  Private psychiatric set up – nursing home.  Out patient private practice.  Private general.
Substance Abuse, Medication Adherence, and Criminality among Mentally Ill Parolees David Farabee & Sylvia Sanchez UCLA Integrated Substance Abuse Programs.
CCTN September 6 th, Recent Scientific Publications from the Clinical Trials Network David Liu, M.D. (CTN-0029) Harold Perl, Ph.D. (CTN-0015) Paul.
ACAMPROSATE Efficacy Results from Three Pivotal Efficacy Trials Karl F. Mann, M.D. Professor and Chairman Director, Department of Addictive Behavior and.
Raymond F. Anton, MD for The COMBINE Study Research Group
Participants were recruited from 6 drug free, psychosocial treatment (PT) and 5 methadone maintenance (MM) programs (N = 628) participating in a NIDA Clinical.
Measuring Outcome in the Treatment of Cocaine Dependence Paul Crits-Christoph, Ph.D. Mary Beth Connolly Gibbons, Ph.D. Robert Gallop, Ph.D. Jaclyn S. Sadicario,
Impact of transient and persistent personality disturbance on the outcome of anxiety and depressive disorders Professor Peter Tyrer (Imperial College,
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Temperament and Character Adaptations to Addictions Treatment Daniel Angres, M.D.¹ &Stephanie Bologeorges, B.A.¹ ¹ Resurrection Behavioral Health-Addiction.
Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter.
Which factors predict outcome in the nonoperative treatment of patellofemoral pain syndrome? A prospective follow-up study Kannus P, Nittymaki S. Med.
Abstinence Incentive Effects in Psychosocial Counseling Patients Testing Stimulant Positive vs Negative at Treatment Entry Maxine L. Stitzer Johns Hopkins.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Introduction Results and Conclusions Analyses of demographic and social variables revealed that women were more likely to have children, be living in a.
Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.
Schizoaffective Disorder in Life
1 Impact of Implementing Designed Nursing Intervention Protocol on Clinical Outcome of Patient with Peptic Ulcer By Amal Mohamed Ahmad Assistant Professor,
Vivia V. McCutcheon, Howard J. Edenburg, John R. Kramer, Kathleen K. Bucholz 9 th Annual Guze Symposium St. Louis, MO February 19, 2009 Gender Differences.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
BECK DEPRESSION INVENTORY Angela M. Theobald Fort Hays State University.
 What is ADHD?  A chronic disorder  Begin during early childhood and continues to adolescence  Can be full or partial clinical picture in 60% of patients.
Buprenorphine {Suboxone®, Subutex®}
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
Dr. Adair, Is Marijuana really addictive? J. Randle Adair, D.O., Ph.D. Diplomate, American Board of Internal Medicine Certified, American Society of Addiction.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
This presentation uses information freely available from: NICE Guidance CG115 2 nd. Edition - August 2011 CG115 Alcohol dependence and harmful alcohol.
Changing adolescent substance use and criminal activity in juvenile drug court: Improving outcomes through family-based treatment Gayle Dakof, Craig Henderson,
©2016 MFMER | slide-1 Patient screening tools associated with prediction of depression remission at six months Kurt B. Angstman, MS MD Professor of Family.
Medication Assisted Treatment for Opioid Use Disorders
©2015 MFMER | slide-1 PTSD: Worsening outcomes for comorbid depression… even with collaborative care management. Kurt B. Angstman, MS, MD Professor of.
1 What happens to smokers in the first few weeks after stopping smoking? Robert West University College London Practical Cardiology, Oxford September 2007.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
L.S. Remy1, G. Woody2, K. Lynch2, K. M. Kampman2
Copyright © 2003 American Medical Association. All rights reserved.
The role of Emotion Regulation Difficulties and Anxiety Sensitivity
CAREGIVER BURDEN AMONG CAREGIVERS OF PERSONS WITH DEMENTIA AND LATE ONSET DEPRESSIVE DISORDER AND ITS ASSOCIATION WITH PERCEIVED ELDER ABUSE Presenter:
ABCs of Behavioral Support
Assessing Opioid Use Disorder, part 1
buprenorphine-naloxone
Treatment for PTSD and SUD:
Results: Specific Aim 2 (cont.)
Overview of Secondary Outcome Domains
Medications used in Treatment of Alcohol and Drug Use Disorders
Presentation transcript:

Experience in developing a tool using the CSSA as a model Kyle M. Kampman M.D. Professor Department of Psychiatry Perelman School of Medicine University of Pennsylvania MOST Meeting 25 March 2015

Developing the CSSA as an outcome measure What is the CSSA?What is the CSSA? Where did it come from?Where did it come from? What does it measure?What does it measure? Basic reliability and validity testingBasic reliability and validity testing Subsequent testing and usefulness in clinical trialsSubsequent testing and usefulness in clinical trials

What is the CSSA? Cocaine Selective Severity Assessment - It is a measure of cocaine withdrawal - It is a measure of cocaine withdrawal - 18 Item each measured on a 0-7 scale - 18 Item each measured on a 0-7 scale - Signs and symptoms measured include: - Signs and symptoms measured include: appetite changessleep changes appetite changessleep changes cocaine cravingdepressed mood cocaine cravingdepressed mood anxiety irritability anxiety irritability lethargy inattention lethargy inattention paranoia heart rate changes paranoia heart rate changes

Where did the CSSA come from? CSSA written by Joe Volpicelli at Penn CSACSSA written by Joe Volpicelli at Penn CSA Modeled on the Selective Severity Assessment for alcohol (Gross 1973)Modeled on the Selective Severity Assessment for alcohol (Gross 1973) Intended to assist in the management of cocaine withdrawal syndromeIntended to assist in the management of cocaine withdrawal syndrome

Cocaine withdrawal as a syndrome Gawin and Kleber Arch Gen Psychiatry 1986;43:

Cocaine withdrawal and subjective effects Depression increases cocaine high (Uslaner, 1999; Sofuoglu, 2001) Irritability increases cocaine high (Newton, 2003) Cocaine Withdrawal Increases the Cocaine High

Cocaine withdrawal and subjective effects Cocaine Withdrawal Increases the Cocaine High Sofuoglu et al. Drug Alcohol Depend 2003; 69:

Cocaine withdrawal and hedonic dysregulation Several studies report that the presence of severe cocaine withdrawal symptoms at baseline predicts poor clinical outcome Craving Hedonic Dysregulation WD

The CSSA 18 Items Interviewer administered 2 craving scales One total score

Psychometric testing Initial reliability and validity testing 1.Test retest reliability 2.Interrater reliability 3.Internal consistency 4.Concurrent validity 5.Predictive validity Kampman et al. Addict Behav (4):

CSSA: concurrent validity Individual items correlate with DSM-IV criteria Depressed moodDepressed mood LethargyLethargy Increased appetiteIncreased appetite Increased sleepIncreased sleep IrritabilityIrritability

CSSA: concurrent validity Individual items correlate with ASI severity measures –More days of cocaine use –Longer lifetime history of cocaine use –Higher ASI Severity scores for drug problems

CSSA: concurrent validity Specific to cocaine withdrawal Specific to cocaine withdrawal

CSSA: concurrent validity Scores decline over time if a patient becomes abstinent Scores decline over time if a patient becomes abstinent

CSSA: predictive validity High CSSA Scores Predict Poor Outcome 1. Psychotherapy trial, University of Pennsylvania Completed 30 Days of Treatment Mulvaney et al., JSAT 1999;16(2): * * p =.005

CSSA: predictive validity High CSSA Scores Predict Poor Outcome 2. Day Hospital, Philadelphia VAMC Completed 30 Days of Treatment Kampman et al. Psychol Addict Behav. 2001;15(1):52-9. * *p =.001

CSSA : predictive validity High CSSA Scores Predict Poor Outcome 3. Medication Trial, University of Pennsylvania 3 Consecutive Weeks of Abstinence Kampman et al., Addict Behav. 2002;27(2): * * p <.001

Identifying predictors in cocaine dependence treatment Subjects and measures 7 clinical trials 7-12 weeks duration Cocaine dependent only ASI, UDS 2-3 weekly, TLFB self-report Predictor variables Baseline ASI Baseline UDS CSSA scores Outcome variables Three weeks of continuous abstinence 50% reduction ASI Composite Drug Score No self reported cocaine use last 4 wks of the trial

Demographics and baseline drug use data N 402 Age 39 (6.8) % African-American 81% % men 75% Years of education 13 (1.9) % crack smokers 87% Days coc. use (past 30) 13 (9.3) Years coc. Use (lifetime) 9.9 (6.0) $ for drugs (past 30) $606 (850) ASI Comp. Drug Score.230 (.08) CSSA score 27 (18) (standard deviation)

Baseline predictors. 3 Weeks of Continuous Cocaine Abstinence Model  2 (P) 50% Reduction in ASI Composite Drug Scores Model  2 (P) Self-Reported Abstinence, Last 4 Weeks of Treatment Model  2 (P) Age Gender.80.37< Yrs education Days coc. Use (past 30)24.6< <.001 Yrs coc use (lifetime) Days alc. Use (past 30) < Yrs alc use (lifetime) Initial UDS23.9< <.001 Initial CSSA score16.5< <.001 Bough et al. Neuropsychopharmacology. 2014;39(1):202-19

Low CSSAHigh CSSA AmantadinePlacebo Number of Clean Urine Samples CSSA and medication response: amantadine Amantadine Improved Abstinence Kampman et al., Am J Psychiatry. 2000;157(12):

CSSA and medication response: propranolol Propranolol Improves Outcome in High CSSA Patients Retention Urinary BE Levels Kampman et al., Drug Alcohol Depend. 2001;63(1):69-78.

CSSA and medication response; topiramate Kampman et al. Drug Alcohol Depend. 2013;133(1):94-9.

CSSA as an outcome measure CSSA Scores in Treatment Mean CSSA scores tend to decline over time in medication trials No differences in CSSA scores over time in several trials topiramate modafinil acamprosate naltrexone (oral) naltrexone (extended release injectable) varenicline piracetam disulfiram olanzapine ginko biloba theobromine amantadine *propranolol – reduced withdrawal symptoms in 1 st trial not 2 nd

Discussion The CSSA is an good predictor of outcome in outpatient cocaine dependence treatmentThe CSSA is an good predictor of outcome in outpatient cocaine dependence treatment The CSSA may identify subgroups responsive to particular medications – propranolol and topiramate for exampleThe CSSA may identify subgroups responsive to particular medications – propranolol and topiramate for example No medication tested has shown a differential response in reducing CSSA scores.No medication tested has shown a differential response in reducing CSSA scores.

Individual CSSA Items as Predictors. 3 Weeks of Continuous Cocaine Abstinence Model  2 (P) 50% Reduction in ASI Comp. Drug Scores Model  2 (P) Self-Reported Abstinence, Last 4 Weeks of Treatment Model  2 (P) Hyperphagia Hypophagia Carb. Craving Coc. Crav. intensity22.0< <.001 Coc. Crav. frequency17.0< Bradycardia Decreased Sleep Increased sleep Anxiety Cocaine craving and bradycardia were the most consistent predictors of outcome.

Predictors of psychosocial treatment outcome Retention Outpatient N=87 Retention Day Program N=97 Abstinence Med Trial N=76 High CSSA Scores Predict Poor Outcome Abstinence Coc/alc N= 80